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Short report
Atypical HNPCC owing to MSH6 germline
mutations: analysis of a large Dutch pedigree
A Wagner, Y Hendriks, E J Meijers-Heijboer, W J F de Leeuw, H Morreau, R Hofstra,
C Tops, E Bik, A H J T Bröcker-Vriends, C van der Meer, D Lindhout, H F A Vasen,
M H Breuning, C J Cornelisse, C van Krimpen, M F Niermeijer, A H Zwinderman,
J Wijnen, R Fodde
Abstract
Hereditary non-polyposis colorectal can-
cer (HNPCC) is the most common genetic
susceptibility syndrome for colorectal
cancer. HNPCC is most frequently caused
by germline mutations in the DNA mis-
match repair (MMR) genes MSH2 and
MLH1. Recently, mutations in another
MMR gene,MSH6 (also known as GTBP),
have also been shown to result in HNPCC.
Preliminary data indicate that the pheno-
type related to MSH6 mutations may
diVer from the classical HNPCC caused
by defects inMSH2 andMLH1.
Here, we describe an extended Dutch
HNPCC family not fulfilling the Amster-
dam criteria II and resulting from aMSH6
mutation. Overall, the penetrance of
colorectal cancer appears to be signifi-
cantly decreased (p<0.001) among the
MSH6 mutation carriers in this family
when compared with MSH2 and MLH1
carriers (32% by the age of 80 v >80%).
Endometrial cancer is a frequent mani-
festation among female carriers (six out of
13 malignant tumours). Transitional cell
carcinoma of the urinary tract is also
relatively common in both male and
female carriers (10% of the carriers).
Moreover, the mean age of onset of both
colorectal cancer (MSH6 v MSH2/MLH1 =
55 years v 44/41 years) and endometrial
carcinomas (MSH6 v MSH2/MLH1 = 55
years v 49/48 years) is delayed. As previ-
ously reported, we confirm that the pat-
tern of microsatellite instability, in
combination with immunohistochemical
analysis, can predict the presence of a
MSH6 germline defect.
The detailed characterisation of the
clinical phenotype of this kindred contrib-
utes to the establishment of genotype-
phenotype correlations in HNPCC owing
to mutations in specific mismatch repair
genes.
(J Med Genet 2001;38:318–322)
Keywords: hereditary non-polyposis colorectal cancer;
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Hereditary non-polyposis colorectal cancer
(HNPCC) is one of the most common
autosomal dominant conditions predisposing
to cancer. HNPCC carriers are at risk for the
development of a broad spectrum of malig-
nancies including tumours of the colon,
endometrium, stomach, small intestine, hepa-
tobiliary system, ureter, renal pelvis, and
ovary.1 HNPCC is caused by germline muta-
tions in DNA mismatch repair (MMR) genes,
predominantly MSH2 on chromosome 2p162
and MLH1 on chromosome 3p21.3 In a minor-
ity of cases, mutations have been described in
other MMR genes like PMS1 and PMS2.4
Recently, germline mutations in the MSH6
gene on chromosome 2p15 were recognised as
a frequent cause of atypical HNPCC, that is,
not complying with the clinical “Amsterdam
criteria”.5–9
The involvement of MMR genes in HNPCC
is reflected by the occurrence of instability of
simple repetitive DNA sequences (microsatel-
lite instability or MSI) in tumours from
HNPCC patients. Accordingly, more than
90% of the colorectal tumours and at least 75%
of the endometrial tumours from HNPCC
patients display MSI.10–12 In sporadic colorectal
and endometrial cancer, MSI is found in about
15-30% of tumours.13 14
The first reports on MSH6 germline muta-
tions have indicated that the clinical phenotype
of the aVected families may diVer from the
“classical” HNPCC caused by MSH2 and
MLH1 mutations.5–9 The penetrance of colo-
rectal cancer seemed to be reduced. However,
endometrial cancer was likely to represent a
more important clinical manifestation among
female MSH6 carriers. The reported mean age
of onset of colorectal and endometrial cancer
appeared to be delayed in families with MSH6
germline mutations, 50 years and older com-
pared to 44 (MSH2) and 41 (MLH1) years of
age15 and 53 years and older compared to 49
(MSH2) and 48 (MLH1) years, respectively.7
Notably, MSI analysis of tumours from MSH6
mutation carriers suggested a reduced pen-
etrance of the MSI-H phenotype and preferen-
tial instability at mononucleotide repeats.7–9 12
Here, we report the clinical and molecular
characterisation of a large HNPCC kindred






























































Accepted for publication 15
February 2001
www.jmedgenet.com
 on 27 November 2006 jmg.bmj.comDownloaded from 
resulting from a frameshift mutation in the
MSH6 gene.
Patients
The proband, a 50 year old female, was referred
to the Department of Clinical Genetics,
Rotterdam by her gynaecologist in 1993. At
that time, three of her six sisters were
diagnosed with endometrial cancer at 50, 57,
and 60 years of age. A fourth sister had devel-
oped ovarian cancer (endometroid adenocarci-
noma) at the age of 50. The proband’s father
died at the age of 85 without any symptoms of
HNPCC. Her mother underwent a hysterec-
tomy for leiomyomata at 55 and was in good
health at 92 years of age.
The diVerential diagnosis in this family
included HNPCC. Mutation analysis of the
MLH1 and MSH2 genes by PCR and DGGE
in one of the aVected sisters of the proband did
not show any pathogenic mutation. In the
meantime, the proband developed endometrial
cancer at the age of 53, the fourth case of
endometrial cancer in this sibship.
As soon as MSH6 mutation analysis became
available, mutation screening was performed
and a frameshift mutation (del T codon 594) in
exon 4 was identified.7 The proband, her
aVected sisters, and mother were found to
carry the same mutation.
At the request of the proband, family mem-
bers were informed about the findings and
were invited to contact the Department of
Clinical Genetics for additional information
and/or to be tested for the presence of the
mutation.
We were also able to link the family to
another kindred under investigation at the
Department of Clinical Genetics at the Leiden
University Medical Centre.
Mutation analysis
In total, DNA testing for the MSH6 mutation
was performed in 80 out of 132 living relatives
with at least a 25% risk of being carrier of the
MSH6 mutation (fig 1), 27 males (out of 63,
43%) and 53 females (out of 69, 77%). Out of
these 132 relatives, 11 were previously diag-
nosed with an HNPCC related tumour and all
of them were tested. Two tested unaVected
relatives were obligate carriers. Out of 75 carri-
ers at 50% risk and 44 at 25% risk, 46 (61%)
and 21 (48%) were tested, respectively (tables
1 and 2).
Ten of the 11 aVected subjects were carriers
of the familial MSH6 mutation. The patient
(IV.6) negative for the mutation was a 55 year
old male, diagnosed with numerous tubulovil-
lous adenomas at the age of 53. Since his clini-
cal presentation was suggestive of familial
adenomatous polyposis (FAP), though with a
delayed age of onset, mutation analysis of the
APC gene was performed. This did not show
any alteration.
The MSH6 mutation was confirmed in both
unaVected obligate carriers.
Out of the 46 tested healthy subjects with a
50% risk for the mutation, 17 (37%) were
found to carry the MSH6 mutation; none of
those with a 25% risk tested positive (table 2).
All 17 unaVected mutation carriers above the
age of 25 years (five males and 12 females) were
oVered the generally accepted surveillance for
HNPCC, namely colonoscopy every one to two
years, yearly gynaecological examination with

































































































































Figure 1 Pedigree of MSH6 family. C = colorectal cancer. E = endometrial cancer.
U = urinary tract cancer. P = polyp. O = ovarian cancer. B = breast cancer. Bt = brain
tumour. Ca? = cancer of unknown origin. + = MSH6 mutation positive. − = MSH6
mutation negative.
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(for female carriers), and yearly urine sediment
testing and cytology. During the first screening
the following diagnoses were made: a tubulovil-
lous adenoma with dysplasia in the proximal
rectum of a 60 year old male; an invasive ductal
adenocarcinoma of the breast and an adenocar-
cinoma of the colon in a 49 year old female; a
small tubular adenoma and endometrial hyper-
plasia in a 50 year old female; and an adenoma
in a female aged 48. Of the remaining 13
carriers, four were under the age of 45 and four
were above 70 years without any symptoms of
the genetic predisposition. However, a 92 year
old female underwent a hysterectomy because
of leiomyomata of the uterus at the age of 55.
The family included five dead obligate
mutation carriers, three females and two males.
Three of them had been diagnosed with a
HNPCC related tumour (table 1). One male
reached the age of 83 without having developed
any HNPCC related tumour.
We were not able to determine the MSH6
status of five cancer patients in this family: one
colorectal cancer (onset >70) in a female
patient (III.13) whose 13 descendants tested
negative for the mutation; one male with an
astrocytoma (III.19) at the age of 75, three of
whose four children did not carry the muta-
tion; two breast cancer patients (IV.14, IV.20,
onset >50); and one patient with cancer of
unknown origin around the age of 40 (III.6).
In total, 34 mutation carriers (29 alive and
five dead) were identified in this pedigree, 17 of
whom developed a (pre)malignant tumour
(table 1). Of the carriers with a malignancy,
four had two primary HNPCC related tu-
mours. Using the Kaplan-Meyer method, 7%
of the carriers developed colorectal cancer by
the age of 50 years and 32% by the age of 80
years (mean age of onset 55 years, ranging from
32 to 83 years). Of the female carriers, 52%
developed endometrial cancer by the age of 80
and all of them were diagnosed above the age of
50 years. Three carriers had a papillary transi-
tional cell carcinoma of the urinary tract (10%
of the carriers).
Microsatellite instability (MSI) and
immunohistochemical (IHC) analyses
We performed MSI analysis and/or immuno-
histochemistry with antibodies against MLH1,
MSH2, and MSH612 on tumour samples
derived from 12 subjects; in four cases, two
independent tumour samples were tested
(table 3).
Using the markers recommended by Boland
et al,16 MSI analysis showed variable patterns
(table 3). However, all tumour samples derived
from the MSH6 carriers displayed instability of
at least one mononucleotide marker when an
extended set of markers, including BAT40, was
used.
Immunohistochemical (IHC) analysis of the
MSH6 protein in tumour sections showed no
expression in any of the samples tested, with




II.2 Colorectal cancer 60 Obligate carrier
III.2 Transitional cell carcinoma right pyelum 77 Obligate carrier
& transitional cell carcinoma left ureter 79
III.4 Transitional cell carcinoma 78 +
III.6 Unknown 40 Not tested
III.11 Endometrial carcinoma ? Obligate carrier
Colon carcinoma >70
III.13 Colon carcinoma >70 Not tested
III.18 Colon carcinoma 83 +
III.19 Astrocytoma 75 Not tested
IV.4 Transitional cell carcinoma ureter 59 +
IV.6 Multiple adenomatous polyps of the colon 53 −
IV.8 Adenoma 50 +
IV.9 Adenoma 48 +
IV.11 Tubulovillous adenoma 60 +
IV.13 Endometrial & rectal carcinoma 55 +
IV.14 Breast cancer 51 Not tested
IV.15 Breast & colon carcinoma 49 +
IV.20 Breast cancer >50 Not tested
IV.26 Endometrial carcinoma 57 +
IV.27 Endometrial carcinoma 60 +
IV.30 Endometroid adenocarcinoma ovary 50 +
IV.32 Endometrial carcinoma 53 +
IV.33 Endometrial carcinoma 50 +
V.8 Colorectal cancer 32 +
+ indicates the presence of the MSH6 mutation.
− indicates the absence of the MSH6 mutation.
Table 2 Results of mutation analysis
Male Female Total
Pretest risk 100%* 50% 25% 100%* 50% 25%
Tested 5 15 7 8 31 14 80
MSH6+ 4 4 0 8 13 0 29
MSH6− 1 11 7 0 18 14 51
Not tested 0 19 17 0 10 6 52
Total 5 34 24 8 41 20 132
*Relatives with an HNPCC related tumour and obligate carriers.
Table 3 Microsatellite and immunohistochemical analysis in tumours from 12 aVected relatives
Subject
III.2 III.4 III.13 III.18 IV.4 IV.6 IV.13 IV.15 IV.26 IV.27 IV.30 IV.32
Tumour type U U U C C U U P R E C B E E O E
Microsatellite status H H L NT H H L S H L S H H L H S
Mononucleotide markers
BAT25* + + + NT + + − − + − − + + − + −
BAT26* NT + − NT + + + − + + − + + + + −
BAT40 + + + NT + + +/− − + + + + NT + + +
Dinucleotide markers
D2S123* + NT − NT − − NT − − − − − − − − −
D5S346* − + − NT + − − − + − − − − − − −
D17S250* + NT − NT + − − − + − − − − − − −
Immunohistochemistry
MLH1 NT NT + ++ + + NT + + ++ + + + + ++ +++
MSH2 NT NT + ++ ++ + NT + − + + + ++ + + ++
MSH6 NT NT − + − − NT + − − − − − − NT −
* = markers recommended by NCI for MSI analysis.16 + = Unstable. − = Stable. NT = not tested/not conclusive. H = MSI high according to NCI recommenda-
tions.16 L = MSI low according to NCI recommendations.16 S = MSI stable according to NCI recommendations.16 C = colon tumour. U = urinary tract tumour.
E = endometrial tumour. O = ovarian tumour. R = rectal tumour. P = polyp. B = breast tumour.
Immunohistochemistry: +++ = strong staining, ++ = moderate staining, + = weak staining, − = no staining.
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the exception of III.13 and IV.6. Patient III.13
could not be tested for either the presence of
the germline mutation or for MSI, and is likely
to represent a phenocopy, in view of the late
age of onset (colon carcinoma at >70 years)
and the failure to detect the MSH6 mutation
in her 13 descendants. We were able to
perform MSI analysis in a single adenoma
from patient IV.6 that did not display
instability for any of the tested markers.
MLH1 and MSH2 IHC analysis was positive
in all samples with the exception of the
rectal carcinoma from IV.13, negative for
MSH2.
Discussion
Genetic heterogeneity and variable phenotypic
expression represent major complications in
the diagnosis and clinical management of
HNPCC, one of the most common inherited
predispositions to multiorgan tumorigenesis.
Although the hallmark of this condition is rep-
resented by colorectal lesions, a broad range of
cancer types, including tumours of the en-
dometrium, stomach, small intestine, hepato-
biliary system, and ureter, are established clini-
cal expressions of HNPCC. The vast majority
of HNPCC cases are known to result from
germline mutations in the DNA mismatch
repair genes MSH2 and MLH1.17 In these kin-
dreds, high penetrance and early onset of
colorectal and endometrial cancer are the
major clinical features. The set of diagnostic
criteria, Amsterdam criteria I and II, estab-
lished by the International Collaborative
Group on HNPCC18 19 well serve the purpose
of selecting families with a high likelihood of
carrying MSH2 and MLH1 mutations.17 More
recently, atypical HNPCC families, that is, not
complying with the Amsterdam criteria (ACI
and II) though clearly suggestive of a HNPCC-
like inherited condition, have been reported to
be caused by germline mutations in a third
MMR gene, namely MSH6.7–9 Preliminary
phenotypic analysis of these families showed a
reduced occurrence of colorectal cancer and a
prevalence of endometrial tumours.
Here, we have presented a detailed analysis
of an extended Dutch HNPCC pedigree
resulting from an inactivating germline muta-
tion of the MSH6 gene.
The expression of the MSH6 mutation in
this family suggests a reduced penetrance and a
delayed age of onset for colorectal cancer.
Using the Kaplan-Meyer method, 7% of the
carriers developed colorectal cancer by the age
of 50 years and 32% by the age of 80 years.
This is significantly reduced (p<0.001) com-
pared to “classical” HNPCC caused by MSH2
and MLH1 (∼55% by age 50 and >80% by age
80).15 Admittedly, these calculations are based
on a limited number of cases and may
represent an overestimate because not all
healthy eligible relatives were tested for the
MSH6 mutation. Moreover, the selection bias
introduced when studying a family with such a
striking clinical history may also lead to an
overestimation of the penetrance. The mean
age of onset of the colorectal carcinomas in this
family is 55 years. This is delayed when
compared with HNPCC families caused by
MSH2 (44 years) and MLH1 (41 years) muta-
tions.15 This delayed age of onset may also bias
the estimated penetrance. Notably, the young-
est diagnosed case was at 32 years, implying
that periodic screening recommendations
should not diVer from those established for
classical HNPCC until more data are available.
In this family, endometrial cancer is the most
common tumour type (six out of 13 malignant
tumours) among female carriers. All the
endometrial cancers were diagnosed above the
age of 50 and their mean age of onset was 55
years, that is, five to 10 years later when
compared with “classical” HNPCC caused by
mutations in MLH1 and MSH2.7 20
Another striking clinical phenotype in this
family is the papillary transitional cell carci-
noma of the ureter and renal pelvis observed in
three relatives (10% of the carriers). Notably,
the lifetime cumulative risk of this tumour type
in MLH1 or MSH2 mutation carriers is only
2.6%.21
As previously reported by us and others,7–9
the MSI phenotype caused by loss of MSH6
function is reduced when compared with
MLH1 and MSH2, and diVers in its predomi-
nance at mononucleotide runs. This is in
agreement with previous studies on yeast and
mouse model systems.22 23 From this point of
view, the set of markers previously recom-
mended by NCI for MSI analysis16 may not be
suitable for MSH6 mutation carriers and
should be complemented with a set of
mononucleotide markers. In six of the cases
reported here (III.4, IV.4U, IV.13E, IV.15C,
IV.27, and IV.32) (table 3), instability was
observed at only one or two mononucleotide
repeats (one of which was not included in the
NCI panel) leading to an MSI-low or stable
classification. In five of these cases, IHC was
performed and indicated the loss of MSH6 in
the tumour. Therefore, we recommend IHC
analysis in MSI-L and MSS tumours from
cases with a family history suggestive of
HNPCC.12
We also show the feasibility of the IHC
approach not only on colorectal tumours but
also in carcinoma of the endometrium, urinary
tract, and breast. The latter finding is relevant
for the inclusion of breast cancer in the
HNPCC tumour spectrum: breast tumour
samples from IV.15 showed both MSI-high and
a negative IHC staining pattern in accordance
with the presence of the MSH6 germline
mutation in this person. Two additional
perimenopausal breast cancer cases were found
in the present study (IV.14 and IV.20).
However, as no material was available from
these patients, we could not establish their
MSH6 mutation carrier status.
IHC analysis was also helpful in the
assessment of the likely phenocopy status rela-
tive to III.13. As a limited amount of a colorec-
tal carcinoma was available from this dead
patient, we limited our analysis to IHC and
found normal MSH6 protein expression.
Moreover, all her descendants tested negative
for the mutation. Another dead patient from
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this family, III.19, was diagnosed with astrocy-
toma at the age of 75. Again, no archival mate-
rial was available from this patient. However,
the delayed age of onset and the fact that three
of his children tested negative for the mutation,
do not allow us to draw any conclusion on the
relationship between the presence of the brain
tumour and the MSH6 defect.
Patient IV.6 presented with a clinical pheno-
type more suggestive of attenuated polyposis24
rather than HNPCC. Accordingly, MSI analy-
sis of the colonic polyps was negative (MSS)
and normal MSH6 expression was found by
IHC. Failure to detect the MSH6 mutation in
this patient confirmed that the attenuated
polyposis is likely to result from an unlinked
genetic predisposition.
In conclusion, the clinical features associated
with MSH6 germline mutations strongly sup-
port the inclusion of endometrial cancer and
transitional cell cancer of the ureter and renal
pelvis in the diagnostic criteria for HNPCC in
the new Amsterdam Criteria (ACII) as formu-
lated by the ICG-HNPCC.19 In addition, we
propose to perform MSI in combination with
IHC in all Amsterdam negative families with a
clustering of endometrial or urinary tract can-
cers. The combined MSI and IHC analysis will
direct subsequent mutation analysis for MSH6.
We thank Dr J J P M Pieters, gynaecologist, for referring the
family to the Department of Clinical Genetics, Rotterdam.
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